toreforant orallydosed selective antagonist histamine receptor studied various health conditions successor number compounds developed johnson phase iia clinical trials completed recently november continue suggest toreforant end regulatorapproved antagonist us phase ii clinical trials toreforant show efficacy eosinophilic drug show least partial efficacy rheumatoid arthritis patients nonresponsive receptor widely implicated regulation inflammatory states potential uses antagonist remain pharmacologyrelated article stub help wikipedia expanding httpsenwikipediaorgwikitoreforant